Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-03-20

Clinical Trial Update: Study of Magrolimab Combinations in Participants With Myeloid Malignancies [Phase 2]

View source ↗

Summary

Phase 2 study evaluating magrolimab combinations in participants with myeloid malignancies was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Magrolimab (magrolimab)

Snippet

Sponsor: Gilead Sciences | Conditions: Myeloid Malignancies | Phase 2 | Status: TERMINATED | Results posted: 2025-03-20